



Oncolmmunology

ISSN: (Print) 2162-402X (Online) Journal homepage: <http://www.tandfonline.com/loi/koni20>

Non-V delta 2 gamma delta T lymphocytes as effectors of cancer immunotherapy

Jonathan Fisher, Anne-Marijn Kramer, Kenth Gustafsson & John Anderson

To cite this article: Jonathan Fisher, Anne-Marijn Kramer, Kenth Gustafsson & John Anderson (2015) Non-V delta 2 gamma delta T lymphocytes as effectors of cancer immunotherapy, *Oncolmmunology*, 4:3, e973808, DOI: [10.4161/2162402X.2014.973808](https://doi.org/10.4161/2162402X.2014.973808)

To link to this article: <http://dx.doi.org/10.4161/2162402X.2014.973808>



© 2015 The Author(s). Published with license by Taylor & Francis Group, LLC



Accepted author version posted online: 23 Dec 2014.
Published online: 23 Dec 2014.



Submit your article to this journal [↗](#)



Article views: 375



View related articles [↗](#)



View Crossmark data [↗](#)



Citing articles: 1 View citing articles [↗](#)

Full Terms & Conditions of access and use can be found at
<http://www.tandfonline.com/action/journalInformation?journalCode=koni20>

Non-V delta 2 gamma delta T lymphocytes as effectors of cancer immunotherapy

Jonathan Fisher¹, Anne-Marijn Kramer², Kenth Gustafsson², and John Anderson^{1,*}

¹Section of Cancer; UCL Institute of Child Health; London, UK; ²Section of Molecular and Cellular Immunology; UCL Institute of Child Health; London, UK

Keywords: gamma-delta T cell, neuroblastoma, ovarian cancer, preclinical, Vdelta-1

Gamma delta T cells ($\gamma\delta$ T) are potent mediators of antitumor cytotoxicity and have shown promising efficacy in early phase clinical trials. Most is known about the tumoricidal properties of cells bearing the V δ 2 T cell receptor chain, but recent studies have demonstrated that cells with the V δ 1 chain and those with neither V δ 1 nor V δ 2 chains have properties which may make them more attractive anticancer effectors in adoptive immunotherapy.

For a cell type to be useful in cancer adoptive immunotherapy it must be amenable to *ex vivo* expansion of potent effectors in a manner that avoids generation of regulatory or suppressive counterparts. With this in mind, numerous cell populations have been evaluated over the past 20 y, including dendritic cells, lymphokine activated killer (LAK) cells, tumor infiltrating lymphocytes, and positively selected natural killer (NK) cells. However, each method has limitations that have precluded widespread clinical adoption. For example, the difficulty in obtaining sufficient numbers of tumor infiltrating lymphocytes for most cancer types, and the expansion of regulatory T-cells in response to IL-2.

$\gamma\delta$ T lymphocytes have also been evaluated for *ex vivo* expansion for adoptive immunotherapy and equally confounding hurdles to overcome have been revealed. While $\gamma\delta$ T cell adoptive immunotherapy using existing technologies demonstrates modest but promising clinical effect,¹ new approaches are required for effective utilization of this unique population of cells.

There are a number of key differences between peripherally circulating $\gamma\delta$ T cells and the more abundant alpha beta T ($\alpha\beta$ T) lymphocytes. Most notably, $\gamma\delta$ T cells recognize targets in an MHC

independent manner, have innate killing activity against pathogens, and appear to respond to self-molecules that signal potential danger or cellular stress. Furthermore, they can differentiate into professional antigen presenting cells (pAPCs), expressing co-stimulatory molecules and presenting antigenic fragments for the primary stimulation of CD4⁺ and CD8⁺ $\alpha\beta$ T-cell responses.^{2,3}

In the peripheral blood of individuals living outside areas of endemic parasitaemia, $\gamma\delta$ T cells expressing the V γ 9V δ 2 TCR are the commonest subset. In parts of Africa, however, the V δ 1⁺ subset predominates,⁴ and there is evidence of extra-thymic changes in $\gamma\delta$ T cell repertoire in response to environmental pathogen exposure. Until recently, almost all human $\gamma\delta$ T cell research focused on the V γ 9V δ 2 subset, due to its relative abundance in Western populations and ease of expanding large numbers of cells for study or adoptive transfer using phosphoantigen ligands of the V γ 9V δ 2 TCR. Deniger and colleagues^{5,6} demonstrated that polyclonal $\gamma\delta$ T cell expansion was possible using an engineered K562 cell line expressing CD86, CD64, 41BBL, and membrane bound IL-15. Using the same artificial antigen presenting cells (aAPC) coated in an anti- $\gamma\delta$ TCR antibody (Biologend clone B1) we

have shown that it is possible to generate >1,000 fold expansion of $\gamma\delta$ T cells from the blood of neuroblastoma patients within 1 mo, preserving the relative distributions of V δ 1⁺, V δ 2⁺ and V δ 1^{neg}/V δ 2^{neg} $\gamma\delta$ T subtypes⁷ (Fig. 1).

V δ 1⁺ and V δ 1^{neg}/V δ 2^{neg} $\gamma\delta$ T cells expanded using aAPC+B1 demonstrate many characteristics that recommend them for cellular immunotherapy over V γ 9V δ 2⁺ cells. Following adoptive transfer, less differentiated cells persist for longer in the recipient. V δ 1⁺ and V δ 1^{neg}/V δ 2^{neg} $\gamma\delta$ T cells show a less differentiated pattern of CD27, CD45RA, and CD62L expression both before and after expansion with aAPC+B1 compared to V δ 2⁺ $\gamma\delta$ T cells. PD-1 is a marker associated with T-cell exhaustion, and has been a key target in therapies aimed at overcoming immune checkpoints.⁸ V δ 1⁺ and V δ 1^{neg}/V δ 2^{neg} $\gamma\delta$ T cells have lower expression of PD-1 compared to both V δ 2⁺ and $\alpha\beta$ T cells after 2 weeks of expansion, which is sufficient to generate around 50-fold expansion in $\gamma\delta$ T cell numbers. Perhaps most significantly however is the striking level of innate cytotoxicity demonstrated by V δ 1⁺ $\gamma\delta$ T cells against solid tumor cell lines. It has been known for some time that phosphoantigen expanded V δ 2⁺ $\gamma\delta$ T cells will kill cell lines from certain

© Jonathan Fisher, Anne-Marijn Kramer, Kenth Gustafsson, and John Anderson

*Correspondence to: John Anderson; Email: j.anderson@ucl.ac.uk

Submitted: 07/30/2014; Revised: 10/01/2014; Accepted: 10/03/2014

<http://dx.doi.org/10.4161/2162402X.2014.973808>

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/3.0>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The moral rights of the named author(s) have been asserted.




Figure 1. Use of artificial antigen presenting cells for unbiased expansion of blood gamma delta T lymphocytes. An antibody against the gamma delta T cell receptor tethered to the aAPC by the high affinity Fc γ Receptor, is responsible for forming an immunological synapse involving the gamma delta TCR.

cells, and especially V δ 1⁺ cells fulfil this wide spectrum of requirements, encouraging the therapeutic exploitation of these subsets. Moreover, their innate cytotoxic mechanisms will result in the release of antigen for uptake. The exposure to tumor antigen will thus activate their expansion and simultaneously activate their role as pAPCs, promoting tumor antigen-specific cytotoxic $\alpha\beta$ T-cell responses.

The propensity of V δ 2⁺ $\gamma\delta$ T cells to activation induced death,¹⁰ combined with their higher levels of differentiation and expression of exhaustion markers⁷ suggest that they may not be the best choice of effector, despite the ease in expanding large numbers. Deniger

et al.'s use of umbilical cord blood as a more naïve source of cells may go some way to overcoming this limitation and is of particular interest.

Therefore, despite the moderate clinical success of V δ 2⁺ $\gamma\delta$ T cell based immunotherapy, there is an opportunity to explore the utility of non-V δ 2⁺ $\gamma\delta$ T cells as adoptive transfer agents. These could be delivered either as selected populations or as polyclonal $\gamma\delta$ T cell preparations, which harness the different antigenic affinities, cytolytic and antigen presentation profiles of each subset.

Disclosure of Potential Conflicts of Interest

No potential conflicts of interest were disclosed.

solid and hematological malignancies, but with only a few exceptions this killing is significantly antibody dependent.¹

We showed that V δ 1⁺ cytotoxicity against the same targets was independent of antibody and not attributable to all-or-eactivity, with killing efficiency equivalent or greater than the ability of V δ 2⁺ $\gamma\delta$ T cells to kill opsonized target cells; V δ 2⁺ cytotoxicity in the absence of opsonizing antibody was minimal. Based on these data, it is perhaps unsurprising that the published clinical trials of $\gamma\delta$ T cell immunotherapy, all of which used V δ 2⁺ cell expansions and none of which combined the therapy with an antitumor antibody, showed only modest efficacy.^{1,9} Comparison of our recent studies with the work of

Deniger et al. highlights differences in the innate cytolytic potential of V δ 2⁺ $\gamma\delta$ T cells following expansion under differing conditions. These differences could be explained by different starting populations (umbilical cord blood vs. PBMC), different cytokines during expansion or different engagement of the $\gamma\delta$ TCR in the models used.

To be useful in cancer immunotherapy, an expanded effector population must possess certain characteristics. They require tumor tropism to infiltrate the tumor in sufficient numbers. Their memory phenotypes must be sufficiently naïve to allow survival in the host following adoptive transfer, and their cytolytic activity must be specific for tumor cells. Non-V δ 2⁺ $\gamma\delta$ T

References

- Fisher JP, Heuvelink J, Yan M, Gustafsson K, Anderson J. $\gamma\delta$ T cells for cancer immunotherapy: a systematic review of clinical trials. *Oncoimmunology* 2014; 3: e27572; PMID:24734216; <http://dx.doi.org/10.4161/onci.27572>
- Himoudi N, Morgenstern DA, Yan M, Vernay B, Saraiva L, Wu Y, Cohen CJ, Gustafsson K, Anderson J. Human $\gamma\delta$ T lymphocytes are licensed for professional antigen presentation by interaction with opsonized target cells. *J Immunol* 2012; 188:1708-16; PMID:22250090; <http://dx.doi.org/10.4049/jimmunol.1102654>
- Brandes M, Willmann K, Moser B. Professional antigen-presentation function by human gammadelta T cells. *Science* 2005; 309:264-8; PMID:15933162; <http://dx.doi.org/10.1126/science.1110267>
- Hviid L, Akanmori BD, Loizon S, Kurtzhals JA, Ricke CH, Lim A, Koram KA, Nkrumah FK, Mercereau-Puijalon O, Behr C. High frequency of circulating gamma delta T cells with dominance of the v(delta)1 subset in a healthy population. *Int Immunol* 2000; 12:797-805; PMID:10837407; <http://dx.doi.org/10.1093/intimm/12.6.797>
- Deniger DC, Switzer K, Mi T, Maiti S, Hurton L, Singh H, Huls H, Olivares S, Lee DA, Champlin RE et al. Bispecific T-cells expressing polyclonal repertoire of endogenous $\gamma\delta$ T-cell receptors and introduced CD19-specific chimeric antigen receptor. *Mol Ther* 2013; 21:638-47; PMID:23295945; <http://dx.doi.org/10.1038/mt.2012.267>
- Deniger DC, Maiti S, Mi T, Switzer K, Ramachandran V, Hurton LV, Ang S, Olivares S, Rabinovich BA, Huls H et al. Activating and propagating polyclonal gamma delta T cells with broad specificity for malignancies. *Clin Cancer Res* 2014; 20(20):5708-19; PMID:24833662; <http://dx.doi.org/10.1158/1078-0432.CCR-13-3451>
- Fisher J, Yan M, Heuvelink J, Carter L, Abolhassani A, Frosch J, Wallace R, Flutter B, Hubank M, Klein N et al. Neuroblastoma killing properties of V-delta 2 and V-delta 2 negative gamma delta T cells following expansion by artificial antigen presenting cells. *Clin Cancer Res* 2014; 20(22):5720-32.

- 8 Hamid O, Robert C, Daud A, Hodi FS, Hwu W-J, Kefford R, Wolchok JD, Hersey P, Joseph RW, Weber JS et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. *N Engl J Med* 2013; 369:134-44; PMID:23724846; <http://dx.doi.org/10.1056/NEJMoa1305133>
- 9 Fournié J-J, Sicard H, Poupot M, Bezombes C, Blanc A, Romagné F, Ysebaert L, Laurent G. What lessons can be learned from $\gamma\delta$ T cell-based cancer immunotherapy trials? *Cell Mol Immunol* 2013; 10(1):35-41.
- 10 Kabelitz D, Pechhold K, Bender A, Wesselborg S, Wesch D, Friese K, Janssen O. Activation and activation-driven death of human gamma/delta T cells. *Immunol Rev* 1991; 120:71-88; PMID:1677929; <http://dx.doi.org/10.1111/j.1600-065X.1991.tb00588.x>